ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research: Recent Episodes
American College of Cardiology
The American College of Cardiology offers select interviews and summaries of cardiology’s most interesting research areas from ACCEL’s renowned library, hosted by ACCEL Editor-in-Chief Alison L. Bailey, MD, FACC, FAACPVR.
In this interview, Dennis Bruemmer MD, PhD and Alison L. Bailey MD FACC, discuss Optimizing the Care of ASCVD Patients with T2DM.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
In this interview, David J. Maron MD, FACC and Richard A. Chazal MD, MACC, discuss Revascularization of Stable Ischemic Heart Disease in the Era of COURAGE, ISCHEMIA, and ORBITA.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
What are the practical considerations when determining the duration of antiplatelet regimens following PCI?
In this interview, Mirvat Alasnag, FACP, FACC, FSCAI, FSCCT, and Sun Moon Kim, MD, FSCAI, FACC, discuss Long-Term Secondary Prevention After PCI or MI: Aspirin, Clopidogrel, DAPT or DPI?
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
In this interview, Harriette GC Van Spall MD, MPH, FRCPC, and Clyde W. Yancy MD, MSc, MACC, FAHA, MACP, FHFSA, FASPC (Hon.), discuss the Basics of HF-rEF and Work Up.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
In this interim report of extended follow-up of ISCHEMIA, with a total of 557 deaths (nearly twice the number of deaths in the initial phase), the probability of a survival benefit at 7 years with either initial management strategy was not different. These findings provide important evidence for patients with chronic coronary disease and their physicians as they decide whether to add invasive management to guideline-directed medical therapy.
In this interview, Judith S. Hochman, MD, FACC, FAHA, William E. Boden MD, FACC, FAHA, and Purvi Parwani MBBS, MPH, FACC, discuss ISCHEMIA-EXTENDed – the Follow-Up Interim Report.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
Statin intolerance is one of the most vexing problems encountered by patients and providers. The CLEAR Outcomes trial directly addresses this problem, using a drug, bempedoic acid, that works only in the liver, thereby reducing the potential for side effects.
In this interview, Steven E. Nissen MD, MACC and Laxmi Mehta MD, FACC, discuss Bempedoic Acid and Cardiovascular Outcomes In Statin Intolerant Patients At High Cardiovascular Risk.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
Obesity is a driver of Type 2 diabetes, hypertension, abnormal lipids and is an independent risk factor for cardiovascular events and death. The recent discovery of medications with robust ability to affect appetite is making successful and maintained weight loss a reality. In individuals with obesity, semaglutide produces 17% weight loss on average and tirzepatide, under review by the FDA, 22% weight loss on average. While cost and expertise in prescribing are still barriers to implementation in practice, these new medications offer promise in fighting the ever rising rates of obesity.
In this interview, Donna Ryan MD and Anthony N. DeMaria MD, MACC discuss When Lifestyle Isn't Enough: Surgical vs. Pharmacological Approaches for Obesity.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
In this interview, Michael J. Ackerman MD, PhD, and Christopher M. Kramer MD, FACC, with Jeffrey Hsu MD, PhD, discuss ACC.23 Late-Breaker: Vigorous Exercise in Individuals with Hypertrophic Cardiomyopathy: Primary Results of the LIVE-HCM Study.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
Patients receiving chemotherapy regimens containing anthracyclines for lymphoma were significantly less likely to show evidence of heart dysfunction after taking atorvastatin for 12 months, according to research from the STOP-CA trial, a multicenter, randomized, double-blind, placebo-controlled study presented at ACC.23/WCC.
In this interview, Bonnie Ky MD, MSCE and Anthony N. DeMaria MD, MACC discuss “Statins To Prevent The Cardiotoxicity From Anthracyclines: The STOP-CA Trial.”
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
Clinicians need more tools to reduce the number of unnecessary tests. Clinical likelihood models represent such tools, and this study demonstrated favorable prognosis for patients who were deferred for testing using the risk factor-weighted clinical likelihood model and the coronary artery calcium score-weighted clinical likelihood model.
In this interview, Simon Winther MD, PhD and Laxmi Mehta MD, FACC discuss JACC piece: CACS Improves Risk Prediction in Patients with Suspected Obstructive CAD.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
The PRECISE trial examined how to evaluate patients with chest pain most effectively, minimizing unnecessary testing.
In this interview, Pamela S. Douglas MD MACC, FASE, FAHA and Richard A. Chazal MD, MACC discuss PRECISE – Comparison of a Precision Care Strategy with Usual Testing to Guide Management of Stable Patients With Suspected CAD.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
Iron deficiency is very common in patients with heart failure, affecting between one third to a half of all patients. IRONMAN will help determine if treatment with intravenous iron can help patients feel better, and reduce the risk of being hospitalized for heart failure or dying.
In this interview, Professor Paul Kalra MD, FRCP and Roger S. Blumenthal MD, FACC discuss IRONMAN – Randomized Trial of Intravenous Ferric Derisomaltose in HFrEF.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
In this contemporary population of statin-treated patients with type 2 diabetes and hypertriglyceridemia, 1 in 10 developed a cardiovascular event by 3 years, and despite 20-30% reductions of triglycerides and what we call remnant cholesterol with a fibrate-like therapy, there was no clinical benefit.
In this interview, Aruna Das Pradhan MD, MPH and Allen J. Taylor MD, FACC discuss PROMINENT – A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of CVD.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
The drug treatments we use to manage atrial fibrillation don't change the progression in the disease.
Catheter ablation, even when performed in younger and healthier patients, modifies the disease trajectory and prevents progression.
In this interview, Jason G. Andrade MD, FRCPC and Christopher M. Kramer MD, FACC discuss AHA Late-Breaker: PROGRESSIVE-AF – The Impact of “First-Line” Rhythm Therapy on Atrial Fibrillation Progression.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
Although lipoprotein(a) is believed to play a causal role in atherogenesis, there are no approved therapies to help lower it. The OCEAN(a) DOSE study examined a drug specifically designed to lower lipoprotein(a) through RNA interference.
In this interview, Michelle L. O'Donoghue MD, MPH and Nanette Kass Wenger MD, MACC discuss AHA Late-Breaker: OCEAN(a)-DOSE – Reduction of Lipoprotein(a) With Small Interfering RNA.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
Patients with chronic kidney disease are at high risk of worsening kidney disease and cardiovascular events. Treatments that can slow down the worsening of kidney disease and reduce the need for dialysis and kidney transplants and the risk of cardiovascular events are potentially of great importance. While diabetes remains the biggest cause of chronic kidney disease, over half of patients with chronic kidney disease do not have diabetes, so treatments that work in people with and without diabetes are key.
In this interview, David Preiss MBChB, MRCP, FRCPath, PhD and Cindy L. Grines MD, FACC, MSCAI discuss AHA Late-Breaker: EMPA-KIDNEY – Empagliflozin and Cardiovascular Outcomes in Patients with CKD.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
A new study examined a very common clinical question of which loop diuretic or water pill is better in patients living with heart failure - torsemide or furosemide? Prior studies suggested that torsemide might be better than furosemide but they had never been compared head-to-head in a large clinical trial.
The TRANSFORM-HF trial compared these 2 therapies against each other.
In this interview, Robert J. Mentz MD and Laxmi Mehta MD, FACC discuss the primary findings of AHA Late-Breaker: TRANSFORM-HF – Comparative Effectiveness of Torsemide versus Furosemide in Heart Failure.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
In this interview, Glenn A. Hirsch MD, MHS, FACC and Alison L. Bailey MD, FACC discuss Top Takeaways from 2022: General Cardiology.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
In this interview, Martha Gulati MD MS FACC FAHA FASPC FESC and Alison L. Bailey MD, FACC, discuss the Top Takeaways from 2022: Preventive Cardiology.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
In this interview, Dipti Itchhaporia MD, FACC and Alison L. Bailey MD FACC discuss the Top Takeaways from 2022 in Interventional Cardiology.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
In this interview, Christopher M. Kramer MD, FACC and Alison L. Bailey, MD FACC discuss the Top Takeaways from 2022 in cardiovascular imaging.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
In this interview, Clyde W. Yancy MD, MSc, MACC, FAHA, MACP and Alison L. Bailey MD FACC, discuss the Top Takeaways from 2022: Heart Failure. Dr. Yancy discusses trials including DELIVER, TRANSFORM-HF, DCP, BRIGhtn, and the ACC/AHA/HFSA Guidelines.
Earlier detection of people at risk of HF would enable cardioprotection to be initiated earlier and damage avoided. Current imaging tools (eg. ejection fraction) are not sensitive enough to identify early disease. While GLS has been shown to predict outcomes, this study shows that its use improves the predictive power of the current definition of stage B HF.
In this interview, Professor Tom Marwick MBBS, PhD, MPH, FAHMS and John Gorcsan III MD, FACC discuss improving characterization of Stage A and B HF by adding strain.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
In an effort to limit unnecessary testing and increase diagnostic yield, current major guideline recommendations recommend a risk-based strategy with deferred testing in low-risk patients, catheterization in high risk patients, and selective noninvasive testing for those at intermediate risk. To date, no randomized trial has explored the clinical efficacy and safety of any such strategy.
In this interview, Pamela S Douglas MD, MACC and Anthony N. DeMaria MD, MACC discuss Real World Implications of 2021 AHA/ACC Chest Pain Guidelines: Modeling of Deferred Testing Recommendations in the PROMISE Trial.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
Thiazides are recommended first line agents for the treatment of hypertension. They have been demonstrated to lower cardiovascular disease. Which thiazide to choose has been a long-standing issue.
In this interview, Areef Ishani MD, MS and W. Douglas Weaver MD, MACC discuss AHA Late-Breaker: DCP – Chlorthalidone Compared to Hydrochlorothiazide for the Prevention of Cardiovascular Events in Patients with Hypertension.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
Ultrasound can make it easier for cardiologists to do procedures including angioplasty or stenting when femoral artery is used.
In this interview, Sanjit Jolly MD, MSc and Matt Cavender MD MPH, FACC, with Sun Moon Kim MD FSCAI, FACC, discuss Routine Ultrasound for Vascular Access.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
In this interview, Martin Halle MD and Steven E. Nissen MD, MACC discuss a recent piece in JACC: Exercise for Primary and Secondary Prevention of Cardiovascular Disease.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
Any person with a smartphone can screen him- or herself for treatment-relevant atrial fibrillation - the world's most important arrhythmia. This could have huge impact on the prevention of stroke.
In this interview, Axel Bauer MD and Thomas F. Deering MD, FACC, with Sun Moon Kim MD, FSCAI, FACC, discuss ESC Late-Breaker: eBRAVE-AF: Smartphone-based AF screening.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
This subgroup analysis from the MASTER-DAPT trial demonstrates that in high-bleeding risk patients with acute or recent myocardial infarction it is safe to stop DAPT 1 month after stenting and that this strategy provides a reduction in bleeding risk.
In this interview, Pieter C. Smits MD, PhD, FESC and Sidney C. Smith Jr. MD, MACC, with Jeffrey Hsu MD, PhD, discuss a recent piece from JACC: Abbreviated Antiplatelet Therapy after Coronary Stenting in Patients with Myocardial Infarction at High Bleeding Risk.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
In the DANCAVAS Trial, researchers found a remarkable reduction in death of any cause, and this might be a game changer in prevention of cardiovascular diseases.
In this interview, Axel Cosmus Pyndt Diederichsen MD and Clyde W. Yancy MD, MSc, MACC, FAHA, MACP, FHFSA, FASPC (Hon.) discuss ESC Late-Breaker: DANCAVAS: screening and intervention to prevent cardiovascular disease.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
As we age we are increasingly challenged by physical activities. Regular exercise is an essential medicine to maintain a level of function that encompasses simple activities as we age. On the flip side, a lack of exercise leads to a lack of heart conditioning that can contribute to a lack of heart capacity resulting in shortness of breath and heart failure with stressors such as illness or physical activity. Does the concept of exercise deficiency apply to all cases of HFPEF?
In this interview, Professor Andre La Gerche MD, PhD and Christopher M. Kramer MD, FACC discuss a recent piece in JACC: HFpEF as an Exercise Deficiency Syndrome.
Marfan Syndrome is a rare genetic heart disease, but still affects over a million people worldwide. It causes swelling of the main blood vessel of the heart, which can even tear if major surgery is not performed - usually when the patient is in their 20s or 30s. Researchers form Oxford University worked with teams all over the world to combine results from several trials involving almost 1500 patients - the most powerful study of its kind - and found that two widely available medicines, angiotensin receptor blockers and beta-blockers, work both separately and in combination to slow the rate of expansion of the blood vessel, potentially delaying the need for surgery and the risk of tearing by a decade or more if the drugs are taken together long term.
In this interview, Alex Pitcher, MD and William E. Boden MD, FACC, FAHA, with Sun Moon Kim MD FSCAI FACC, discuss the ESC Late-Breaker: MTT: Assessing the Effects of ARBs and Beta-Blockers in Marfan Syndrome.
INOCA and MINOCA are conditions with high risk of cardiac events and frequent persistent ischemic symptoms, and aggressive intervention is needed to reduce risk and symptom burden. This episode will review the data on contemporary treatment of INOCA and MINOCA and discuss additional strategies beyond the data and future directions.
In this interview, Jamieson Bourque, MD., MHS., FACCE and Magnus Ohman MD, FACC, with Michelle D. Kelsey MD, ask if there is evidence for treatment, and discuss data-driven management of in-patients with INOCA and MINOCA.
We have never had a symptoms-based guideline before. Why was it time for these new Chest Pain Guidelines? How does shared decision-making come into the assessment of chest pain? Is anatomic or functional testing preferred in the evaluation or acute chest pain or stable chest pain?
In this interview, Martha Gulati MD MS FACC FAHA FASPC FESC and Christopher M. Kramer MD, FACC, with Nosheen Reza MD, discuss the top controversies behind the Chest Pain Guideines.
In this interview, Francesco Franchi, MD and Spencer B. King III, MD, MACC, with Matt A. Cavender MD, MPH, FACC, discuss how to make the best choice when selecting an oral P2Y12 inhibitor post-MI.
The highly anticipated newest iteration of the Chronic Heart Failure Guidelines are finally here. What updates are most important to clinicians, and how can they be most effectively implemented in clinical practice?
In this interview, Michelle Kittleson MD, PhD and Clyde W. Yancy MD, FACC, with Hilary Shapiro, MD MSc, discuss how to implement the new HF Guidelines into your practice.
Any of us could suffer a nonfatal cardiac arrest. Sudden cardiac arrest is not limited to patients with heart disease. Even athletes could have a sudden and unexpected cardiac arrest. We must be prepared as society (external defibrillators and CRP) but also as cardiologists (to perform the correct studies).
In this interview, Manlio Marquez, MD, FACC and Jeroen J. Bax PhD, MD, FACC, with Zain Ul Abideen Asad MD, discuss how one should perform an investigation of a survivor of sudden cardiac arrest.
What do the new Chest Pain Guidelines say about additional noninvasive testing for low risk and intermediate risk patients? Is relief of chest pain with nitroglycerin diagnostic of myocardial ischemia?
In this interview, Debabrata Mukherjee, MD, MS and Jeroen J. Bax PhD, MD, FACC, with Jonathan R. Salik, MD, discuss these questions and other top takeaways for the practicing clinician: from the Chest Pain Guidelines.
Death due to pulmonary embolism remains high, despite increased attention and advances in various medications and treatment techniques. Surgical treatment of acute PE is safe and highly effective at saving lives.
In this interview, Joshua B. Goldberg, MD and C. Noel Bairey Merz MD, FACC, with Michelle D. Kelsey MD, discuss Modern Managment of High-Risk PE.
Peri-partum cardiomyopathy is a form of heart failure affecting young mothers during later stages of pregnancy or early post-partum. Medical management should be tailored to improving the mother's health while ensuring safety of the baby.
Which of the currently available heart failure drugs are safe in pregnancy and during breast feeding? What are the outcomes of women with peripartum cardiomyopathy, who undergo LVAD implantation or heart transplantation?
In this interview, Dharini Ramu, MD, FACC and Spencer B. King III, MD, MACC, with Yuvraj Chowdhury MD, discuss Medical and Advanced Heart Failure Therapies in Peri-partum cardiomyopathy: A Cardiologist’s Perspective.
Women with preeclampsia and related hypertensive disorders of pregnancy have increased risk of heart disease compared with women who experienced uncomplicated pregnancy. Women should ensure treating clinicians know their reproductive history, and clinicians should work to aggressively prevent and treat development of cardiovascular risk factors in women with a history of preeclampsia.
In this interview, Michael Honigberg, MD, MPP, FACC and Glenn A. Hirsch MD, MHS, FACC, with Yuvraj Chowdhury MD, discuss Pre-Eclampsia: Maternal Red Flag of Risk.
The United States is the only developed country with rising rates of death during pregnancy and up to one year postpartum. The maternal mortality crisis is disproportionately impacting women of color, specifically Black women who are 3 times as likely to die. This is regardless of education, income or profession and most notably is as a result of psychosocial stressors, including racism.
In this interview, Rachel M Bond, MD, FACC and Alison L. Bailey, MD FACC, with Michelle D. Kelsey MD, discuss Black Maternal Health: A Call to Action and Implications for Prevention.
When can COVID survivors return to play? In this interview, Nicole Martin Bhave, MD, FACC, FASE and Eugene Ho-Joon Chung, MD, discuss the ACC Expert Consensus Decision Pathway on COVID-19: Return to Play.
Post-COVID, cardiovascular symptoms may persist or emerge more than 4 weeks after infection. Identifying people with cardiovascular disease sequelae is an important first step. However, many people have cardiovascular syndromes that are not easily identified on standard cardiac testing. More research is needed to better understand these syndromes. In the meantime, we need to come together as a community to share best practices and maximally support patients so that they can return to their daily lives.
In this interview, Erica Sarah Spatz, MD, FACC and Alison L. Bailey, MD, FACC, with Tiffany Y. Hu, MD, discuss ACC Expert Consensus Decision Pathway on COVID-19: Post-acute Sequelae.
Attack of the heart muscle by the immune system (myocarditis) is a rare but serious complication of SARS-CoV-2 infection, and an even more rare complication of COVID-19 mRNA vaccination.
In this interview, Larry A. Allen, MD, MHS, FACC and Tyler J. Gluckman, MD, FACC, FAHA, discuss the ACC Expert Consensus Decision Pathway on COVID-19: Myocarditis.
Chronic inflammatory diseases are associated with accelerated atherosclerosis. Psoriasis in particular accelerates the formation of high risk coronary plaque which drives heart attack and stroke. Providers and patients need to be aware of these associations.
In this interview, Nehal N. Mehta, MD MSCE and W. Douglas Weaver MD, MACC, with Matt A. Cavender MD, MPH, FACC, discuss Inflamed! Populations at Risk for Inflammation Associated CVD.
Which changes to the ACC/AHA/SCAI Coronary Artery Revascularization Guidelines will have the greatest impact to the patient? Which of the published “Top Ten Take-Away Messages” is most important?
In this interview, Jacqueline E. Tamis-Holland, MD, FACC, FAHA, FSCAI and Roxana Mehran MD, FACC, with Yuvraj Chowdhury MD, discuss Most Significant Changes from the Prior Coronary Artery Revascularization Guidelines.
What is clinical problem with regard to leaflet thrombosis after TAVR, and what are the main findings of the ADAPT-TAVR trial?
In this interview, Duk-Woo Park, MD and Sun Moon Kim MD, with Zaid I. Almarzooq MBBCh, discuss Late Breaker: Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial.
In this interview, Steven E. Nissen, MD, MACC and Anthony N. DeMaria MD, MACC, with Anum Saeed MD, discuss the ACC.22 Late Breaker: Magnitude and Duration of Effects of a Short-interfering RNA Targeting Lipoprotein(a): A Placebo-controlled Double-blind Dose-ranging Trial.
Suzanne Oparil, MD, FACC, FAHA, FASH, FAPS and Nanette Kass Wenger MD, MACC, discuss ACC.22 Late Breaker: Antihypertensive Therapy For Mild Chronic Hypertension Improves Pregnancy Outcomes: A Pragmatic Multicenter RCT.
In this interview, Steven E. Nissen, MD, MACC and Anthony N. DeMaria MD, MACC, with Anum Saeed MD, discuss the ACC.22 Late Breaker: Magnitude and Duration of Effects of a Short-interfering RNA Targeting Lipoprotein(a): A Placebo-controlled Double-blind Dose-ranging Trial.
This study evaluates the potential impact of Mavacamten in severely symptomatic patients with obstructive hypertrophic cardiomyopathy to reduce the need for septal reduction therapy. It studies a first of its kind new cardiac myosin inhibitor.
In this interview, Milind Desai MD, MBA and Matthew Martinez MD, FACC, with Zain Ul Abideen Asad MD, discuss this ACC.22 Late Breaker: Mavacamten as an Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Clinicians often recommend dietary sodium reduction for almost all their patients with HF. Whether or not this practice should continue remains an uncertain question in almost every clinic visit. We spend a fair amount of time counselling patients on this, and patients want to know if they need to undertake a full change in their diet to improve how they feel or function, and if this changes will increase or decrease the chance of being in the hospital again.
In this interview, Justin A. Ezekowitz, MBBCh, MSc and Steven E. Nissen MD, MACC, with Yuvraj Chowdhury MD, discuss Late Breaker: SODIUM-HF: Study Of Dietary Intervention Under 100 Mmol In Heart Failure.
Heart failure patients experience exercise intolerance and functional limitation every day. While the targeting of functional capacity is an important unmet need, this study found that the change in peak oxygen uptake did not differ between patients taking omecamtiv mecarbil and placebo.
How do current guideline-directed medical therapies for heart failure impact exercise capacity? How does omecamtive mecarbil differ from other heart failure pharmacotherapies?
In this interview, Gregory Lewis, MD and Jeroen J. Bax PhD, MD, FACC, with Ioannis Mastoris, MD, MPHcand, discuss Late Breaker: METEORIC-HF: The Effect Of Omecamtiv Mecarbil On Exercise Tolerance In Patients With Chronic HFrEF.
Heart failure patients are generally multi-morbid and at risk for hyperkalemia, which makes treatment with life-saving therapies like RAASi difficult and leads to compromised medical treatment and in turn poor outcomes. This trials showed that with the use of patiromer, one can simultaneously lower the risk of hyperkalemia and increase optimal medical therapy for heart failure with reduced ejection fraction.
In this interview, Javed Butler, MD MPH MBA, Anthony N. DeMaria MD, MACC, with Ioannis Mastoris, MD, MPHcand, discuss the Late Breaker: DIAMOND trial: Patiromer For The Management Of Hyperkalemia In Subjects Receiving Renin-angiotensin-aldosterone System Inhibitor Medications For Heart Failure With Reduced Ejection Fraction.
TTR amyloidosis is increasingly recognized as a cause of diastolic heart failure and as much more common than previously thought. There are proven and investigational therapies that can slow or possibly stop this disease.
In this interview, Rodney H. Falk, MD, FACC and Alison L. Bailey, MD FACC, with Jonathan R. Salik, MD, discuss Screening for Transthretin Amyloid Cardiomyopathy in Everyday Practice.
Genetics can establish a baseline lifelong trajectory for cardiovascular disease risk for everyone. Learn the latest about testing, actionability, and limitations as well as future directions.
In this interview, Pradeep Natarajan, MD, MMSc and Steven E. Nissen, MD, MACC, with Manuel Rivera Maza, MD, discuss When Is Genetic Testing Helpful?
In this interview, Benjamin D. Levine, M.D., FACC, FAHA, FACSM and Richard A. Chazal MD, MACC, with Arav Jhand MD, discuss athletes with underlying coronary artery disease: Special Considerations in Cardiovascular Screening, Evaluation and Management.
What digital and wearable technologies are patients using to change their lifestyle behaviors? What is the clinician’s role in helping patients to use wearables and digital tools to help them live healthier lives, and what are the benefits?
In this interview, Elizabeth A. Jackson, MD, MPH, FAHA, FACC and Roger S. Blumenthal MD, FACC discuss Helping Patients Improve Lifestyle Behavior in the Digital Era.
Cardiac amyloidosis is an often overlooked and thus misdiagnosed form of a restrictive cardiomyopathy in which delayed diagnosis is associated with significant morbidity and mortality. Immunoglobulin light chain (AL) cardiac amyloidosis is the most deadly from of cardiac amyloidosis but significant progress has been made in treatment with the first FDA approved therapy for this condition - daratumumab.
In this interview, Mathew Maurer, MD and Stephen J. Nicholls, MBBS, PhD, FACC, with Yuvraj Chowdhury, MD, discuss Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis--Focus on AL.
It is important that patients with reduced heart function are treated with drugs that have been documented to prolong survival. In this interview, Finn Gustafsson, MD, PhD and Michelle Kittleson MD, FACC, along with Michael Mikolaj MD, MPH, FACC, discuss What Should Optimal Medical Therapy Look Like Prior to Intervention?
After a heart attack, levels of blood lipids such as low-density lipoprotein cholesterol (LDL-C) may influence the risk of further cardiovascular events. In this analysis, we determined that even when LDL-C levels are controlled with a statin, elevated levels of another blood lipid called lipoprotein(a) are associated with an increased risk of further cardiovascular events and a benefit of treatment with the PCSK9 inhibitors.
In this interview, Gregory G. Schwartz, MD, PhD and Glenn A. Hirsch MD, MHS, FACC, with Lindsay Panah, MD, discuss Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients with Nominally Controlled LDL-Cholesterol.
Is atrial fibrillation ablation a "slam dunk" for athletes? When would a clinician favor pharmacotherapy?
In this episode, Michael S. Emery, MD, MS, FACC debates Mark S Link, MD on Atrial Fibrillation Management in Athletes, moderated by Alison L. Bailey, MD FACC.
Studies have demonstrated dysfunction of the left atrium and right atrium were linked to lower ability to walk, and may be a precursor to heart failure. It may be useful to examine the function of the atria on echocardiography to understand one's risk of developing heart failure in the future.
In this interview, Ravi B. Patel, MD, MSc and Roger S. Blumenthal MD, FACC, with Aaysha Cader, MBBS, MD, MRCP, discuss Associations of Cardiac Mechanics with Exercise Capacity: The Multi-Ethnic Study of Atherosclerosis.
Use of the newer high-sensitivity troponins offer significant advantages, but with a number of caveats. Although the ability to accelerate the exclusion of myocardial infarction in many patients within just a few hours of ED presentation, the increased sensitivity can potentially lead to diagnostic confusion as more patients will have detectable troponin indicating myocardial injury not associated myocardial infarction.
In this interview, Michael C Kontos, MD, FACC, Ana Barac MD, PhD, FACC, with Aaysha Cader, MBBS, MD, MRCP, discuss High-Sensitivity Troponin in The ED: Pearls And Pitfalls of Wide-spread Utilization.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
Syncope occurs commonly in the general population and apart from risks of injury due to physical collapse, they can cause patients considerable anxiety and diminished quality-of-life. Better understanding of the syncope 'landscape' can help practitioners provide more effective prevention strategies while permitting patients to cope more effectively with fears of recurrences.
In this interview, David G Benditt, MD, FACC, FHRS, FESC, FRCPC, CCDS and Thomas F. Deering MD, FACC discuss The Serious (and Not So Serious) Side of Faints and Falls: Is My Syncope Patient at Increased Risk?
Related References:
-
ACC/AHA/HRS Versus ESC Guidelines for the Diagnosis and Management of Syncope: JACC Guideline Comparison. J Am Coll Cardiol 2019;74:2410–2423.
-
Benditt DG, van Dijk JG, Krishnappa D, Adkisson WO, Sakaguchi S. Neurohormones in the Pathophysiology of Vasovagal Syncope in Adults. Front Cardiovasc Med 2020;7:76.
Explore the timing of aortic valve replacement, the choice between TAVI vs. SAVR, and special considerations in the management of aortic stenosis. In this interview, Catherine Otto, MD, FACC and Uma Narasimhan Srivatsa MBBS, FACC, with Matt A. Cavender MD, MPH, FACC, discuss Putting it All Together: Guidelines in the Management of Aortic Stenosis.
In this interview, Dhanunjaya "DJ" Lakkireddy, MBBS, FACC, Andrew Kates, MD, FACC and Alison L. Bailey, MD FACC, discuss their top takeaways from 2021 in electrophysiology and general Cardiology.
In this interview, Christopher M. Kramer, MD, FACC, Deepak L. Bhatt, MD, and Alison L. Bailey, MD FACC discuss their top takeaways from 2021 in cardiovascular imaging and interventional cardiology. Join these ACCEL Leaders as they walk through the most impactful advances of the year.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
In this interview, Clyde W. Yancy, MD, FACC, C. Noel Bairey Merz, MD, FACC and Alison L. Bailey, MD, FACC discuss their top takeaways from 2021 in heart failure and preventive cardiology. These ACCEL Leaders discuss new data regarding SGLT2is, the association of SGLT2i and quality of life measured by KCCQ strata and done so in an entirely virtual space. These are major new data points and infer intriguing new ways to generate original data. What is the message for implementation and cost? Dive into new aspirin data and guidance, COVID myocarditis, and the STEP and ORION trials in this episode.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
Failure to initiate an SGLT2i to an eligible HFrEF patient exposes the patient to higher risk of early post-discharge death and readmission, and the real risk that the medication never gets prescribed at all.
In this interview, Stephen J. Greene, MD and Christopher B. Granger MD, FACC, with Ioannis Mastoris, MD, MPH, discuss In-Hospital Initiation of Sodium Glucose Cotransporter-2 Inhibitors for Heart Failure with Reduced Ejection Fraction.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
Right ventricular pacing induced cardiomyopathy and heart failure is common in patients receiving a high degree of ventricular pacing. It may also be preventable or treatable through the use of conduction system pacing (CSP) or biventricular pacing for cardiac resynchronization therapy (CRT) in patients with left ventricular (LV) dysfunction.
In this interview, Gaurav A. Upadhyay, MD, FACC, FHRS and Joseph Marine MD, MBA, FACC, with Carlos E. Vargas, DO, discuss RV Pacing Induced Cardiomyopathy: Mechanisms, Predictors and Management.
Subscribe on Apple Podcasts | Subscribe on Google Play
Personalizing care in the digital world has always been a challenge because of administrative burden and interoperability issues. The future is already here and we have the chance to leverage remote patient monitoring properly to engage patients with the convenience factor and help patients to be self-advocates of their care.
In this interview, Drs. L. Kristin Newby chats with Dr. Andrew Freeman, Mehmet Kazgan, MSc, MBA, and Shimoli V. Shah about innovations in remote patient monitoring and what it can bring to a practice.
Like what you hear? Get 20 episodes/month with CME/MOC credit! www.acc.org/ACCEL
We need to close the gap in urban versus rural response times, and the time to defibrillation is the critical question. What unique challenges do rural communities face, and how was this compounded over the last year by COVID?
In this interview, Jennifer Monti, MD, MPH and Sherry-Ann Brown MD, PhD, FACC, FAHA, with Arav Jhand MD, discuss how at-home AEDs could positively impact rural communities.
Like what you hear? Get 20 episodes/month with CME/MOC credit! www.acc.org/ACCEL
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
This week we bring you a sample of the CardioNutrition program airing on ACC’s CardiaCast podcast. Enjoy!
The recent prevention guideline from the American College of Cardiology recommends that all adults should consume a healthy diet that emphasizes the intake of vegetables, fruits, nuts, whole grains, lean vegetable or animal protein, and fish and minimizes the intake of trans fats, processed meats, refined carbohydrates, and sweetened beverages. Counseling and caloric restriction are recommended for achieving and maintaining weight loss in the overweight or obese. In this episode, Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC and Robert J. Ostfeld, MD, MSc, FACC discuss a Mediterranean Dietary Pattern.
Key Takeaways:
- A Mediterranean dietary pattern includes vegetable, fruits, legumes, whole grains, fish, lean animal proteins and limits highly processed foods.
- Compared to a more typical Western dietary pattern, a Mediterranean dietary pattern is associated with improved cardiovascular outcomes
Amiodarone monitoring: are existing guidelines outdated? In this interview, A. John Camm, MD, FACC and Uma Narasimhan Srivatsa MBBS, FACC, with Tiffany Y. Hu, MD, discuss Amiodarone monitoring in 2021.
Like what you hear? Get 20 episodes/month with CME/MOC credit! www.acc.org/ACCEL
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
As the number of women of childbearing age with heart disease grows, the importance of safe and effective birth control counseling for pregnancy planning is more important than ever. Which contraceptive methods are optimal for women with cardiovascular disease?
In this interview, Kathryn J. Lindley, MD, FACC and Laxmi Mehta MD, FACC, with Lindsay Panah, MD, discuss Contraception and Reproductive Planning for Women with Cardiovascular Disease.
Like what you hear? Get 20 episodes/month with CME/MOC credit! www.acc.org/ACCEL
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
This study investigates the efficacy and safety of finerenone, compared with a placebo to reduce clinically important cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes when added to the standard of care, which includes glucose-lowering therapies, and maximum-tolerated, labelled doses of either an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker.
In this interview, Bertram Pitt, MD and Michelle L. O’Donoghue MD, FACC, with Michael Mikolaj MD, MPH, FACC, discuss ESC Late Breaker: FIGARO-DKD: finerenone in patients with chronic kidney disease and type 2 diabetes.
Like what you hear? Get 20 episodes/month with CME/MOC credit! www.acc.org/ACCEL
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
This large, multicentre, randomized trial was conducted with patients at high risk for bleeding who had undergone biodegradable polymer sirolimus-eluting stent implantation to assess whether one month of dual antiplatelet therapy preserves the net and major adverse cardiovascular events. And if so, whether it mitigates major or nonmajor clinically relevant bleeding occurrences, compared with longer treatment durations.
In this episode, Prof Marco Valgimigli, MD, PhD, FESC and Poonam Velagapudi MD, MS discuss ESC Late Breaker: MASTER DAPT: dual antiplatelet therapy after coronary stenting in high bleeding risk patients.
Like what you hear? Get 20 episodes/month with CME/MOC credit! www.acc.org/ACCEL
In this interview, Jeroen Bax, PhD, MD, FACC; Stefan Anker, MD, PhD; and Sherry-Ann Brown, MD, PhD, FACC, discuss the ESC Congress 2021 late breaker EMPEROR-Preserved, which evaluates the effect of empagliflozin for risk of cardiovascular death and hospitalisation for patients with heart failure and a preserved fraction with and without diabetes. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.
In this interview, Michelle O’Donoghue, MD, FACC; John Teerlink, MD, FACC; and Jeffrey Hsu, MD, PhD, discuss the effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in the GALACTIC-HF trial. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.
In this interview, Laxmi Mehta, MD, FACC, and Ole Frobert, MD, PhD, and discuss the ESC Congress 2021 late breaker IAMI. This study evaluates whether influenza vaccination improves outcomes in patients with recent MI. Influenza vaccine reduced the risk of the primary composite endpoint of all-cause death, MI, and stent thrombosis. Influenza vaccine also reduced two of the three key secondary endpoints. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.
In this interview, Michelle Kittleson, MD, FACC, and Steffen Desch, MD, discuss the ESC Congress late-breaker TOMAHAWK, which examined whether immediate coronary angiography in survivors of out-of-hospital cardiac arrest and no ST-segment elevation is beneficial with regard to all-cause mortality at 30 days, compared with initial intensive care assessment with delayed/selective angiography. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.
In this interview, Andrea Russo, MD, FACC; Marek Jastrzebski, MD, PhD; and Jeffrey Hsu, MD, PhD, focus on a Heart Rhythm Society late-breaking study on LBB optimized CRT, discussing its differences from traditional pacing and benefits to the patient, limitations of the alternative techniques, and a new method to more fully restore physiology of depolarization of the LV in patients with HF and broad QRS complex. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.
Geriatric principles impact the utility, performance, and interpretation of CV imaging tests. Considering geriatric principles can improve the patient experience during CV testing and the application of test results to clinical care. In this interview, Jeroen Bax, PhD, MD, FACC; Jim Kirkpatrick, MD, FACC; and Akhil Narang, MD, FACC, discuss the clinical utility and age-related challenges of CV imaging in older patients. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.
Should we deprescribe statins after age 75, or could this commonly used heart medication benefit other conditions of aging? How does cognitive function relate to vascular health, and could statins be useful? In this interview, Annabelle Volgman, MD, FACC; Karen Alexander, MD; and Taimur Safder, MD, MPH, discuss primary prevention and statins in adults over the age of 75 and the PREVENTABLE study, now enrolling. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.
Observational studies suggest a benefit with PCI in patients with HF, but randomized data comparing PCI versus medical therapy or PCI versus coronary artery bypass grafting on outcomes and myocardial recovery are lacking. In this interview, Roxana Mehran, MD, FACC; Puja Parikh, MD, MPH, FACC; and Maya Ignaszewski, MD, discuss a recent JACC State-of-the-Art Review on the impact of PCI on outcomes in patients with HF. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.
The new universal heart failure (HF) definition will be easier for patients and clinicians to understand and will provide standardization across different societies. In this interview, Allen Taylor, MD, FACC; Biykem Bozkurt, MD, PhD, FACC; and Michelle Kelsey, MD, discuss the new definition and stages of HF and their impacts. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.
Many patients will undergo magnetic resonance imaging (MRI) in their lifetimes. It is important to know that, in most cases, it is possible to perform these scans on patients with a pacemaker as long as appropriate precautions are taken. In this interview, Joseph Marine, MD, MBA, FACC; Andrea Russo, MD, FACC; and Zain Ul Abideen Asad, MD, discuss how to manage the patient with a pacemaker who is undergoing MRI. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.
In this interview, Kim Williams MD, MACC; John William “Bill” McEvoy, MB, BCh, MHS; and Michelle Kelsey, MD, discuss whether to use aspirin for primary prevention in adults >70 years old with subclinical atherosclerosis. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.
In this interview, Andrea Natale, MD, FACC, and Gregory Piazza, MD, FACC, discuss what you need to know about hypercoagulability in a nutshell. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.
The causes of heart attacks are shifting in this era of better control of cholesterol, blood pressure, and smoking and fewer instances of fatty plaque rupturing and causing blood clots. But a different cause of clots seems to be on the rise: superficial erosion. The underlying cause of clots is a hot research area because we can learn how to personalize treatment of acute heart attacks instead of using a one-size-fits-all approach. In this interview, Deepak Bhatt, MD, FACC; Peter Libby, MD, FACC; and Matt Cavender, MD, MPH, FACC, share a vascular biology update on vulnerable plaques. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.
Atrial fibrillation and heart failure coexist in many patients; what is the best management plan for them? In this interview, Uma Narasimhan Srivatsa, MBBS, FACC; Anthony Tang, MD; and Anthony J. Mazzella, MD, discuss RAFT-AF (A Randomized Ablation-Based Atrial Fibrillation Rhythm Control Versus Rate Control Trial in Patients With Heart Failure and High Burden Atrial Fibrillation). For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.
Severe aortic stenosis may go unrecognized, and therefore untreated, in the setting of a low gradient, even if all data point to the existence of a low-flow, low-gradient state and a severe degree of stenosis. In this interview, Mirvat Alasnag, MB, BCH, FACC; Patricia Pellikka, MD, FACC; and Matt Cavender, MD, MPH, FACC, discuss when low-flow, low-gradient aortic stenosis is considered severe. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.
As HF therapy continues to evolve, barriers like medication cost and non-adherence may impede patient care. Pharmacists can overcome these barriers through collaborative practice agreements and patient and provider education. In this interview, Sean Pinney, MD, FACC; Brad Williams, PharmD; and Nosheen Reza, MD, discuss strategies to maximize doses and introduce new medications in a busy practice. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.
The ATLANTIS trial will change the way antithrombotic treatments are chosen after successful transcatheter aortic valve implantation. In this interview, Roxana Mehran, MD, FACC; Jean-Philippe Collet, MD; and Zaid I. Almarzooq, MBBCh, discuss anti-xa oral anticoagulation after valve implantation for aortic stenosis. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.
Telemedicine use has surged over the past year, and this may pose a risk to the quality of care if standards aren't applied to its practice and use. In this interview, Alison Bailey, MD, FACC; Jeff Wessler, MD, MPhil, FACC; and Estefania Oliveros, MD, MSc, discuss the challenge of increasing utilization of telemedicine without robust data. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.
In this interview, Spencer King III, MD, MACC; Michael Reardon, MD; and Michelle Kelsey, MD, discuss the natural history of asymptomatic severe aortic stenosis and the association of early intervention with outcomes. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.
Current guidelines recommend implantable cardioverter-defibrillators (ICDs) in nonischemic cardiomyopathy (NICM) among patients with heart failure and ejection fraction ≤35%. Should this change? Should cardiac resynchronization therapy pacemakers be considered in patients with NICM and left bundle branch block? What were the data to support the use of ICDs for primary prevention in NICM? In this episode, Rachel Lampert, MD, moderates a debate between Michael R. Gold, MD, PhD, and Eric N. Prystowsky, MD, FACC, about whether primary prevention ICDs are still a valuable therapy in patients with NICM. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.
The benefits and risks of fish oil derivatives remain controversial. STRENGTH (Long-Term Outcomes Study to Assess Statin Residual Risk With Epanova in High Cardiovascular Risk Patients With Hypertriglyceridemia) showed no benefits from administration of high doses of a carboxylic formulation containing both eicosapentaenoic acid and docosahexaenoic acid, but it did show an increase in risk of atrial fibrillation. In this interview, Steven E. Nissen MD, MACC; Stephen J. Nicholls MBBS, PhD, FACC; and Michael Mikolaj MD, MPH, FACC, discuss STRENGTH and whether omega-3 fatty acids produce net benefit or harm. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.
In this interview, Peter McCullough, MD, MPH, FACC; Steve Ommen, MD, FACC; and Poonam Velagapudi, MD, MS, discuss top takeaways from the 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.
Many older patients find it difficult to take many medications, especially if the medication regimens of "polypharmacy" are complicated, but would we ever consider deprescribing life-extending medications? In this interview, Laxmi Mehta MD, FACC; James N. Kirkpatrick, MD, FACC, FASE, Chair of ACC Geriatrics Section; and Payal Kohli MD, FACC, discuss polypharmacy in the geriatric patient. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.
Clinicians who want to lower the odds of major cardiovascular and all-cause morbidity and mortality in their patients can recommend physical activity and exercise. In this interview, Alison L. Bailey, MD, FACC; Carl "Chip" Lavie, MD; and Purvi Parwani, MBBS, MPH, FACC, discuss the ideal amount and modality of physical exercise for favorable modification of cardiovascular disease risk. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.
Genetic testing is the fundamental tool of a contemporary vision of medicine called precision medicine, in which the unique characteristics of a patient are used to make important clinical decisions. In this interview, Joseph Marine, MD, MBA, FACC; Sylvia Priori, MD, PhD; and Henry D. Huang, MD, FACC, discuss practical tips to incorporate genetic testing into your cardiovascular practice. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.
Should clinicians consider rescanning 3 to 7 years after a coronary artery calcium (CAC) score of 0? In this interview, Renee Bullock-Palmer, MD; Omar Dzaye, MD, PhD; Michael Blaha, MD, MPH; and Yuvraj Chowdhury, MD, discuss a “warranty period” for CAC scoring. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.
Current guidelines recommend measuring out-of-office BP to confirm office BP. The results of a study published in the JACC suggest that home BP measurement may be the best approach for out-of-office BP monitoring. In this interview, Alison Bailey, MD, FACC; Daichi Shimbo, MD; and Nosheen Reza, MD, discuss the reliability of office, home, and ambulatory BP measurements. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.
Based on the SOLOIST-WHF and SCORED trials, there is now evidence to treat patients with HFpEF with SGLT2 inhibitors and to start treatment early in HFrEF and HFpEF. In this interview, L. Kristin Newby, MD, MHS, FACC; Deepak L. Bhatt MD, FACC; and Shashank Sinha, MD, discuss the expanding biology of SGLT2. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.
Patients with cancer presenting with a heart attack are less likely to receive invasive treatment because of perceived risks and poor outcomes. In this interview, Mamas A. Mamas, MA, DPhil, BMBCh; Ana Barac, MD, PhD, FACC; and Sun Moon Kim, MD, discuss a current study showing that patients with cancer admitted with a heart attack receiving invasive treatment gain as much benefit as patients without cancer. For 20+ insider interviews like these every month with CME/MOC credit, subscribe at www.ACC.org/ACCEL.
Increased scientific data and various guidelines now support use of computed tomography coronary angiography (CTCA) in various clinical settings. However, a knowledge gap remains regarding its usefulness in patient care. In this interview, Ron Blankstein, MD; Allen J. Taylor MD, FACC; and Poonam Velagapudi MD, MS, discuss when noninvasive CTCA can be used instead of cardiac catheterization. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL.
Peripartum heart failure can be difficult to recognize because the symptoms may be similar to those of normal pregnancy; however, it’s important to make the diagnosis so that women can receive the correct medications and treatment. In this interview, Michelle Kittleson, MD, FACC; Melinda B. Davis, MD, FACC; and Jeffrey Hsu, MD, PhD, discuss how to recognize and treat peripartum heart failure.
Clinical studies have reported a prevalence of myocardial infarction with nonobstructive coronary arteries (MINOCA) of 5-6% of acute myocardial infarction cases, with a range of 5-15% depending on the population examined. In this interview, Deepak L. Bhatt, MPH, MD, FACC; Vijay Kunadian, MBBS, MD, FACC; and Michelle Kelsey, MD, discuss what MINOCA is and what to do about it.
In this interview, John McMurray, MD, and Alison Bailey, MD, with Nosheen Reza, MD, discuss the use of mineralocorticoid-receptor antagonist and outcomes in heart failure with reduced ejection fraction.
New analyses highlight the atrial fibrillation subpopulations with potential to progress to major morbidity outcomes and permit a reevaluation of the benefits of rhythm control for these endpoints and need for early restoration of rhythm control. In this interview, Sanjeev Saksena MBBS, MD, FACC, and Andrea M. Russo MD, FACC, with Arav Jhand, MD, discuss reinterpreting the AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) study in 2020.
Given the low cost of coronary artery calcium (CAC) testing and the high likelihood that it will change management of the patient, the cost-effectiveness of CAC testing is robust due to better and more accurate targeting of intermediate risk patients to statin and aspirin therapy and promotion of adherence to those therapies. In this interview, Matthew Budoff, MD; C. Noel Bairey Merz, MD, FACC; and Poonam Velagapudi, MD, MS, discuss the cost-effectiveness of CAC testing and statin therapy.
ACCEL Associate Editors Dhanunjaya "DJ" Lakkireddy, MBBS, FACC, and Andrew Kates, MD, FACC, chat with Editor in Chief Alison L. Bailey, MD, FACC, about their top takeaways from 2020 in electrophysiology and general cardiology.
ACCEL Associate Editors Clyde W. Yancy, MD, FACC, and C. Noel Bairey Merz, MD, FACC, chat with Editor in Chief Alison L. Bailey, MD, FACC, about their top takeaways from 2020 in heart failure and prevention.
ACCEL Associate Editors Christopher M. Kramer, MD, FACC, and Deepak L. Bhatt, MD, FACC, chat with Editor in Chief Alison L. Bailey, MD FACC, about their top takeaways from 2020 in imaging and interventional cardiology.
Spontaneous coronary artery dissection (SCAD) is an increasingly recognized cause of myocardial infarction in women, in particular. There has been an explosion of interest and research in this entity in the past 5 years, but much remains to be studied. In this interview, Anthony DeMaria moderates a discussion between Esther Kim and Malissa Wood about what we know and what we don’t know about SCAD.
Medication interactions can pose a significant health risk. Identifying and understanding the degree of interaction and appropriate management allows for optimization of care while minimizing risk. In this interview, Glenn A. Hirsch, Barbara Wiggins, and Henry D. Huang discuss drug-drug interactions of concern in contemporary cardiovascular care.
What is the optimal therapeutic strategy in non-ST-segment elevation acute coronary syndromes (NSTE-ACS) in patients not pretreated with P2Y12 adenosine diphosphate receptor antagonists, and why reduce the time to invasive strategy in NSTE-ACS? In this interview, John Gorcsan, Laurent Bonello, and Arjun Majithia discuss the EARLY trial (Optimal Timing of Intervention in NSTE-ACS Without Pre-Treatment).
Clinicians must understand the appropriate role of catheter ablation in clinical practice. In this episode, A. John Camm moderates a debate between Douglas L. Packer and Peter R. Kowey about whether ablation is still the salvation in the post-CABANA era.
The coronavirus disease 2019 (COVID-19) pandemic has profoundly changed health care delivery worldwide. In this interview, Joseph Marine, Ty Gluckman, and Yuvraj Chowdhury discuss “Case Rates, Treatment Approaches, and Outcomes in Acute Myocardial Infarction During the Coronavirus Disease 2019 Pandemic.” This study adds to the growing body of literature that has noted worsened outcomes among those with non-communicable (non-infectious) diseases during the pandemic. It also reinforces that although social distancing with COVID-19 is recommended, medical distancing is not (#StopMedicalDistancing).
Chest pain is common, and there is no agreement on how best to approach it. In this interview, Michelle O’Donoghue, Pamela Douglas, and Shashank Sinha discuss whether computed tomography angiography or stress test is the best diagnostic for chest pain.
In this interview, Freek Verheugt and Paulus Kirchhof discuss EAST-AFNET 4: Effects of Early Rhythm Control Therapy in Patients with Atrial Fibrillation from ESC Congress 2020. The results of EAST-AFNET 4 could redefine the role of rhythm control therapy for improved outcomes in patients with early atrial fibrillation.
Flu prevention with appropriate use of the influenza vaccine is more important than ever.
In this interview, Matthew Martinez, Nihar Desai, and Michelle Kelsey discuss flu shots and cardiovascular disease prevention for Fall 2020. Does coronavirus alter anything?
In this interview, Alison Bailey, Xiaowen “Wendy” Wang, and Matt Cavender discuss the importance of masking in the COVID-19 era.
In this interview, Mario Gaudino, Gregg Stone, and Deepak Bhatt discuss left main revascularization and scientific issues for optimal patient care decisions.
In this interview, Alison Bailey and Javed Butler discuss new treatments for an old disease: SGLT2 inhibitors in heart failure.
In this interview, Dipti Itchhaporia and Kim Hansen discuss a collaborative meta-analysis of physical activity as a predictor for instant death in myocardial infarction.
In this interview, David Moliterno and Daniel Thuijs discuss the SYNTAX Extended Survival study: Ten-Year Survival after Coronary Artery Bypass Grafting versus Percutaneous Coronary Intervention.
In this interview, Spencer King and Ajay Kirtane discuss EVOLVE Short DAPT (A Single Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated a Bioabsorbable Polymer-Based Everolimus-Eluting Stent).
In this interview, Anthony DeMaria and Finn Gustafsson discuss improving quality of life for patients with advanced heart failure and a left ventricular assist device. What does the evidence tell us?
In this interview, Christopher Granger and Gabriel Steg discuss fish oil: it's all about triglycerides.
In this interview, Spencer King and David Fitchett discuss the relationship between hypoglycemia outcomes and empagliflozin treatment in the EMPA-REG OUTOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients).
In this interview, Allan Jaffe and Michael Blaha discuss the superiority of calcium scoring over risk scores and why calcium scoring should be more broadly performed.
In this interview, Glenn Hirsch and Paul Ridker discuss the Eugene Braunwald Lecture on Future Directions in Cardiovascular Medicine.
In this interview, Ralph Brindis and Christopher Kramer discuss coronary revascularization and why ischemia and viability by cardiac magnetic resonance should guide revascularization.
In this interview, Michael Sketch and John Rumsfeld discuss digital health in cardiology. Are we there yet?
In this interview, Jennifer Mieres and Robert Harrington discuss addressing the chilly climate for women in cardiology.
In this interview, Richard Chazal and Khaldoun Tarakji discuss WRAP-IT (The World-Wide Randomized Antibiotic Envelope Infection Prevention Trial to Reduce Cardiac Implantable Electronic Device Infection).
In this interview, Michelle O'Donoghue and Mandeep Mehra discuss the final analysis of the 1,028 patient cohort outcomes of MOMENTUM 3 (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3).
In this interview, Noel Bairey Merz and Alexandra Lansky discuss atherosclerotic myocardial infarction in young woman and reasons for poor outcomes in that population.
In this interview, Spencer King and Marc Bonaca discuss insights from the DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58) trial, specifically dapagliflozin and outcomes in patients with peripheral artery disease.
In this interview, Deepak Bhatt and Holly Middlekauff discuss what every cardiologist needs to know about vaping.
In this interview, Robert Schwartz and Michael Reardon discuss the Evolut Low Risk trial (Self-Expanding Transcatheter or Surgical Aortic Valve Replacement in Patients at Low Risk of Surgical Mortality).
In this interview, Peter McCullough and Matthew Budoff discuss the association of coronary artery calcification with subsequent cardiovascular disease in DCCT (Diabetes Control and Complications Trial) and the EDIC (Epidemiology of Diabetes Interventions and Complications) study.
In this interview, David Moliterno and Setri Fugar discuss Outcomes of Transcatheter and Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis and Pulmonary Hypertension: A Nationwide Inpatient Sample Matched Analysis.
In this interview, Freek Verheugt and Colin Berry discuss T-TIME, a randomized, double blind, placebo-controlled, parallel group, multicenter clinical trial of low-dose adjunctive alteplase during primary percutaneous coronary intervention.
In this interview, Spencer King and David Wilbur discuss atrial fibrillation, catheter ablation, and the results of the CABANA trial (Catheter Ablation vs Antiarrhythmic Drug Therapy in Atrial Fibrillation).
In this interview, Gerald V. Naccarelli and Stephen D. Wiviott discuss the DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58) trial.
In this interview, Stephen J. Nicholls and Sotirios Tsimikas discuss AKCEA: Safety and Efficacy of AKCEA-APO(a)-to Lower Lipoprotein(a) Levels in Patients with Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial.
In this interview, Noel Bairey Merz and Ron Waksman discuss LRP: Assessment of Coronary Near-Infrared Spectroscopy Imaging to Detect Vulnerable Plaques and Vulnerable Patients.
In this interview, Nanette Wenger and Deepak Bhatt discuss the Primary Results of REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial).
In this interview, Benjamin Scirica and Tom Ford discuss endothelial dysfunction and altered peripheral vascular reactivity in patients with angina and non-obstructive coronary disease.
In this interview, C. Noel Bairey Merz and Gregg W. Stone discuss COAPT: A Randomized Trial of Transcatheter Mitral Valve Leaflet Approximation in Patients with Heart Failure and Secondary Mitral Regurgitation.
In this interview, Carl Pepine and Gregory Lip discuss improved outcomes by integrated care of anticoagulated patients with atrial fibrillation using the simple ABC (Atrial Fibrillation Better Care) Pathway.
In this interview, Erik Magnus Ohman and Jane Margaret Armitage discuss ASCEND, a randomized trial of aspirin versus placebo for primary cardiovascular prevention in 15,480 people with diabetes.
In this interview, Christopher Kramer and Clyde Yancy discuss Disruptive Medicine: Multi-Level Innovative Approaches to Improve Cardiovascular Health in Minority Populations: A Joint Symposium of the Association of Black Cardiologists and the American College of Cardiology.
In this interview, Alfred Bove and Freek Verheugt discuss the science and magic of decision-making: the Hogwarts approach to ischemic heart disease.
In this interview, Eric L. Michelson and Brendan Everett discuss anti-inflammatory therapy with canakinumab and incident type 2 diabetes: a prespecified key secondary endpoint of CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study).
In this interview, Peter A. McCullough and Steven R. Steinhubl discuss mSToPS (A Digital End-to-End, Nationwide, Pragmatic Trial of Screening for Undiagnosed Atrial Fibrillation Within a Health Insurance System Using a Self-Applied ECG Patch: Primary Results of the mHealth Screening to Prevent Strokes).
In this interview, Glenn Hirsch and Ruth Webster discuss TRIUMPH (A Pragmatic Trial of a Low-Dose Triple-Combination Blood Pressure Lowering Pill for Initial Treatment of Hypertension).